BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Market News

Visa’s revenue growth accelerates to 15% as cross-border volume and data processing outpace payments

Moe Alsumidaie by Moe Alsumidaie
October 28, 2026
in Market News
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

Visa’s full-year fiscal 2026 net revenue reached $45.9 billion, up 15% from the prior year, marking the company’s strongest growth in over 15 years excluding post-pandemic recovery and acquisitions. The acceleration from fiscal 2025’s 11.3% growth signals momentum across payments infrastructure even as the company faces $1.7 billion in litigation provisions tied to interchange disputes.

Full-year non-GAAP net income grew 12% to $25.3 billion, or $13.27 per share, up 16% on a per-share basis. The quarter itself delivered $12.1 billion in revenue, a 13% increase, with non-GAAP earnings per share of $3.48, up 17% year-over-year. On a constant-dollar basis stripping currency effects, full-year revenue growth was 14% and per-share earnings growth was 15%, showing that nominal figures were not inflated by favorable exchange rates.

The revenue composition reveals uneven momentum. Data processing revenue, which scales with transaction volume, rose 17% to $23.4 billion for the full year. Service revenue, tied to payments volume in the prior quarter, grew 14% to $19.9 billion. International transaction revenue, the most exposed to cross-border trade, grew only 8% to $15.3 billion despite cross-border volume climbing 13% for the full year and 14% in the fourth quarter. Other revenue jumped 40% to $5.7 billion. Client incentives, the cost of winning and retaining business, rose 16% to $18.3 billion, consuming a larger share of gross revenue.

What it means

The 15% top-line growth masks a divergence between volume growth and pricing power. Payments volume itself grew only 9% for the full year, while processed transactions rose 9% to 281.3 billion. Cross-border volume outpaced domestic volume by a wide margin, growing 13% total and 12% excluding intra-Europe activity. This suggests that Visa’s growth is driven more by international expansion and transaction density than by acceleration in the underlying payment flows.

BullScope TerminalYou just read VISA INC.’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →

The weakness in international transaction revenue is the honest gap the filing leaves open. Cross-border volume climbed 13% yet international transaction revenue grew only 8%, implying either a pricing decline in that segment, a shift in transaction mix toward lower-margin corridors, or both. The company does not break out pricing by geography or explain the delta. This matters because international transaction fees are among Visa’s highest-margin revenue streams; if pricing pressure is eroding there, the 15% headline growth masks a structural headwind.

Operating expenses grew 16% on a non-GAAP basis, outpacing revenue growth of 14% on a constant-dollar basis. Personnel and marketing expenses drove the increase. This suggests Visa is spending to defend share and expand capacity faster than revenue is expanding, a posture consistent with competitive pressure in payments infrastructure. The company’s operating margin, while not disclosed in this filing, is likely compressing from the 60.0% level achieved in fiscal 2025 if expenses are growing faster than revenue.

The $1.7 billion litigation provision for the interchange multidistrict litigation case and other legal matters signals ongoing regulatory and legal risk to the interchange fee model itself. The provision declined from $2.5 billion in the prior year, suggesting some resolution or repricing of risk, but the case remains unresolved and the company’s core revenue model remains under scrutiny.

What to watch

The next material disclosure will come when Visa reports fiscal first-quarter 2027 results, expected in late 2026 or early 2027. Watch for whether international transaction revenue stabilizes or continues to lag volume growth, and whether the company guides to operating margin recovery or accepts a lower structural margin as the cost of growth. Any update on the interchange litigation settlement or regulatory developments would also reset the risk profile of the business.

Source: Visa’s earnings release filed 2026-10-27 with the SEC.

BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.

For the standing yardsticks on Visa: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Visa.

BullScope TerminalYou just read VISA INC.’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Zoetis narrows revenue outlook as U.S. companion animal sales slide, raises profit guidance on margin strength

by Moe Alsumidaie
November 6, 2026
0

Zoetis cut its full-year revenue forecast to $9.220 billion to $9.320 billion, representing organic operational decline of 2 percent to 1 p

Read moreDetails

Viatris Raises 2026 Guidance as Adjusted EBITDA Climbs 9 Percent Year to Date

by Moe Alsumidaie
November 6, 2026
0

Viatris raised the midpoints of its full-year 2026 financial guidance across all key metrics on the strength of nine-month adjusted EBITDA

Read moreDetails

Joby Aviation raises FY26 revenue outlook 15% as eIPP flights and defense contracts accelerate path to certification

by Moe Alsumidaie
November 5, 2026
0

Joby Aviation lifted its full-year 2026 revenue guidance by 15 percent and completed the first crewed eVTOL flights under the federal gover

Read moreDetails

Amgen’s revenue growth slows to 8% as biosimilar competition erodes legacy franchises

by Moe Alsumidaie
November 4, 2026
0

Amgen's third-quarter revenue rose 8% to $10.4 billion, a deceleration from the 10.0% full-year growth rate filed for fiscal 2025. The slow

Read moreDetails

Palantir’s U.S. commercial revenue overtakes government for the first time as quarterly sales accelerate to 96% growth

by Moe Alsumidaie
November 3, 2026
0

Palantir Technologies raised full-year revenue guidance to 91% growth after U.S. commercial revenue surpassed U.S. government revenue in th

Read moreDetails
Next Post

One Drug Is Thriving. The Other Is on Trial. Ironwood's Filing Shows Both at Once.

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

JPMorgan at Its Own Ceiling: What a Record Quarter Tells Us About the Price Tag

July 29, 2026

UPS: The Margin Story the Filings Tell vs. the One the Market Is Buying

September 17, 2026

Evidence Sheet: Palantir Technologies (PLTR)

November 6, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.